Cullinan Therapeutics, Inc. (CGEM)Healthcare | Biotechnology | Cambridge, United States | NasdaqGS
21.70 USD
-0.90
(-3.982%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 21.70 |
Hot Take ↕ | Aug. 22, 2026, 3:12 a.m. EDT
The recent price surge is a dangerous illusion masking a fundamentally broken business. While the stock rallied 30% in the last two weeks, the underlying reality is stark: the company has lost over 70% of its value over the past four years, with revenue collapsing 54% last year and burning through cash at a rapid pace. The balance sheet is deteriorating, with negative free cash flow and no path to profitability visible in the current data. Despite the 'strong buy' analyst ratings, these appear to be based on speculative clinical trial hopes rather than financial substance. The options market confirms this fear, with traders stacking up cheap insurance (deep OTM puts) for a potential collapse, while the statistical forecast models see almost no chance of a short-term bounce. This is a classic value trap where the hype cycle has detached completely from the financials. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.264560 |
| AutoARIMA | 0.264737 |
| AutoTheta | 0.265259 |
| MSTL | 0.273036 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 30% |
| H-stat | 1.79 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 1.92 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.644 |
| Market Cap | 1,396,496,896 |
| Forward P/E | -8.01 |
| Beta | -0.02 |
| Previous Name | Cullinan Management, Inc. |
| Website | https://cullinantherapeutics.com |
As of Aug. 22, 2026, 3:12 a.m. EDT: Speculators are aggressively positioning for a significant downside move, evidenced by massive open interest in deep out-of-the-money puts (strikes 10, 12, 15) expiring late in 2027, which dwarfs call volume. Conversely, call activity is concentrated in the money or slightly out-of-the-money, suggesting a 'long' bias that is heavily hedged by the put wall. The implied volatility skew is extreme, with deep puts trading at premiums far exceeding ATM calls, indicating a market pricing in a high probability of a crash or severe drawdown despite the recent price rally.
| Attribute | Value |
|---|---|
| 52 Week Change | 2.0173564 |
| Address1 | One Main Street |
| Address2 | Suite 1350 |
| All Time High | 59.85 |
| All Time Low | 5.68 |
| Ask | 21.74 |
| Ask Size | 1 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 671,480 |
| Average Daily Volume3 Month | 923,011 |
| Average Volume | 923,011 |
| Average Volume10Days | 671,480 |
| Beta | -0.023 |
| Bid | 16.16 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 5.0 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 21.7 |
| Current Ratio | 8.417 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 22.88 |
| Day Low | 21.565 |
| Debt To Equity | 0.644 |
| Display Name | Cullinan Therapeutics |
| Earnings Timestamp | 1,786,019,400 |
| Earnings Timestamp End | 1,793,881,800 |
| Earnings Timestamp Start | 1,793,881,800 |
| Ebitda | -221,488,992 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -4.804 |
| Enterprise Value | 1,064,029,888 |
| Eps Current Year | -3.16502 |
| Eps Forward | -2.71048 |
| Eps Trailing Twelve Months | -2.99 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 18.492 |
| Fifty Day Average Change | 3.2080002 |
| Fifty Day Average Change Percent | 0.17348042 |
| Fifty Two Week Change Percent | 201.73564 |
| Fifty Two Week High | 23.19 |
| Fifty Two Week High Change | -1.4899998 |
| Fifty Two Week High Change Percent | -0.06425182 |
| Fifty Two Week Low | 5.68 |
| Fifty Two Week Low Change | 16.02 |
| Fifty Two Week Low Change Percent | 2.8204226 |
| Fifty Two Week Range | 5.68 - 23.19 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,610,116,200,000 |
| Float Shares | 48,082,610 |
| Forward Eps | -2.71048 |
| Forward P E | -8.005962 |
| Free Cashflow | -89,228,128 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 109 |
| Fullday Change | -0.9 |
| Fullday Change Percent | -3.9823 |
| Fullday Price | 21.7 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00425 |
| Held Percent Institutions | 1.12581 |
| Implied Shares Outstanding | 64,354,694 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-01-08 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. |
| Long Name | Cullinan Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 1,396,496,896 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_539392639 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-08-28 |
| Net Income To Common | -208,343,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,454,416,084 |
| Number Of Analyst Opinions | 11 |
| Open | 22.6 |
| Operating Cashflow | -159,250,000 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 617 410 4650 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 21.7 |
| Post Market Time | 1,787,959,806 |
| Prev Name | Cullinan Management, Inc. |
| Previous Close | 22.6 |
| Price Eps Current Year | -6.856197 |
| Price Hint | 2 |
| Price To Book | 4.34 |
| Profit Margins | 0.0 |
| Quick Ratio | 8.293 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.09091 |
| Region | US |
| Regular Market Change | -0.9 |
| Regular Market Change Percent | -3.9823 |
| Regular Market Day High | 22.88 |
| Regular Market Day Low | 21.565 |
| Regular Market Day Range | 21.565 - 22.88 |
| Regular Market Open | 22.6 |
| Regular Market Previous Close | 22.6 |
| Regular Market Price | 21.7 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 630,052 |
| Return On Assets | -0.3136 |
| Return On Equity | -0.50298 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 64,354,694 |
| Shares Percent Shares Out | 0.16450001 |
| Shares Short | 10,588,430 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 10,285,963 |
| Short Name | Cullinan Therapeutics, Inc. |
| Short Percent Of Float | 0.2291 |
| Short Ratio | 17.37 |
| Source Interval | 15 |
| State | MA |
| Symbol | CGEM |
| Target High Price | 42.0 |
| Target Low Price | 23.0 |
| Target Mean Price | 32.36364 |
| Target Median Price | 30.0 |
| Total Cash | 334,537,984 |
| Total Cash Per Share | 5.198 |
| Total Debt | 2,071,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.99 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 14.207925 |
| Two Hundred Day Average Change | 7.492076 |
| Two Hundred Day Average Change Percent | 0.5273167 |
| Type Disp | Equity |
| Volume | 630,052 |
| Website | https://cullinantherapeutics.com |
| Zip | 2,142 |